Algorithms, clinical outcomes and digital biomarkers - Next generation endpoints

Adam Butler
Jane Tiller, MD, FRCPsych, MBA, MPhil
Speakers

Anita Bajaj, MD, MPH
Adam Butler
Ariel Dowling, PhD
Ritu Kapur, PhD
Ian Marcus, MS
John Reynders, PhD
Jane Tiller, MD, FRCPsych, MBA, MPhil
Algorithms, clinical outcomes, and digital biomarkers - Next generation endpoints

Introduction: Jane Tiller
Disclosures

• CMO: of Neumora Therapeutics
• Scientific Advisory Board: Woebot Therapeutics
• Independent Board Member: Longboard Therapeutics

• Thanks to Katherine Scangos for sharing her slides
Increasing Interest in Digital Biomarkers in CNS

Opportunities

- Provides unique insights to quantify and characterize patient subtypes relevant for programs
- Facilitate study execution - via remote data collection. Can and increase the ability of underserved populations to participate in clinical trials
- Measurements can be more frequent or continuous; not restricted by scheduled clinic visits
- Assess disease metrics with objective measures and in patients’ natural environment which may improve their accuracy (reduce noise) and separation of drug/placebo response.
- Opportunity to develop novel endpoints

Challenges

- Immature digital infrastructure – practical deployment
- Significant methodological issues especially with continuous variables
- Verification, analytical and clinical validation
- Black box versus explainable AI

Number of Publications on Digital Measures, Psychiatry

- Smartphone ownership: 44.9% worldwide
- Wearable device usage forecast to reach one billion by 2022
Example: Remote Digital Assessments for Monitoring Change in Major Depression

Jacobson NC et al. npj Digital Medicine 2019

- Standard clinical care for MDD is time-consuming, resource-heavy, and often ineffective.
- Digital measures may allow passive detection of symptom severity changes to monitor
  - Clinical deterioration
  - Treatment response
  - Natural history

**Passive digital biomarkers:** scalable, unobtrusive, time-sensitive, cost-effective

- **Actigraphs:**
  - Movement data captures changes in goal-directed behavior, energy level, and movement
  - Movement data + PPG (HR) sensors estimate changes in sleep onset, duration and architecture

2 wks actigraphy data (actiwatches), N=23 MDD and BP patients
Classification: xgboost, loocv
Predicted the majority of variation in patients’ depression severity over ~2 weeks (MADRS pre-post difference scores).

![Diagnostic Status](chart1)

![Change in Depressive Symptoms](chart2)
**RADAR-MDD Results: Longitudinal Collection of Remote Measures is Feasible**

Faith Matcham et al BMC Psychiatry, 21 Feb (136) 2022 (Jansen and Kings College London)

**RADAR-MDD**: Multi-center, prospective 24 mo observational cohort study; N=623 MDD participants

**Smart-phone data:**
- **Passive**: Global Positioning System (GPS), Bluetooth, gyroscope, phone screen interactions, ambient noise and light levels
- **Active**: questionnaires, cognitive tasks, speech sampling tasks

- Of the 623 participants enrolled, 445 (71.4%) provided outcome data for 1-year, 181 (29.1%) for full 2-years
- Comparable levels of data availability in active and passive forms of data collection
- Higher burden data sources (cognitive tasks, keeping wearable devices charged) reduces data availability

**Fitbit wear-time**: 62.5% across a median study participation of 541 days, and a mean wear-time of 15.1 h per day
DHTS for the passive monitoring of depression: fifty-one studies, N = 16821


Important practical issues identified
- Many digital features correlated with depression – understanding feature importance and practicality vital
- Reasons for dropout: equipment malfunction, technical problems using devices (charging and network connectivity)
- Most studies employed opportunistic study designs, small sample sizes, short follow-up windows (2 wks)

Feature associations with depression by behaviour type.
Conclusions

- Digital Health Technology tools, advanced analytics and application of AI and machine learning have great promise in CNS diseases eg. to quantify behavior, monitor patients in their home environment and to develop novel endpoints.

- However considerable challenges remain, such as: verification and validation, analytical methodology, practical deployment and regulatory considerations which will be the subject of this session.